Global Pantothenate Kinase associated Neurodegeneration (PKAN) Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Global Pantothenate Kinase Associated Neurodegeneration (PKAN) Market Segmentation, By Form (Classic, and Atypical), Diagnostic Test (Genetic Tests, MRI Scan, and Others), Treatment (Anti-Convulsive Drugs, Drugs on Dystonia, and Other Supportive Treatment), End-User (Hospitals, Academic and Research Institutes, Private Clinics, and Others) - Industry Trends and Forecast to 2032

Pantothenate Kinase associated Neurodegeneration (PKAN) Market Size

• The global pantothenate kinase associated neurodegeneration (PKAN) market size was valued at USD 1.43 billion in 2024 and is expected to reach USD 2.36 billion by 2032, at a CAGR of 6.50% during the forecast period
• The market growth is primarily driven by increasing awareness of rare neurodegenerative disorders, coupled with advancements in genetic research and diagnostic technologies. Early and accurate diagnosis of Pantothenate Kinase-Associated Neurodegeneration (PKAN) is critical for timely intervention, which has encouraged adoption of advanced diagnostic tools and therapeutic solutions
• Rising investment in research and development by pharmaceutical and biotech companies is accelerating the development of targeted therapies for PKAN, boosting market expansion. Clinical trials, compassionate use programs, and orphan drug incentives are further stimulating growth in this niche segment

Pantothenate Kinase associated Neurodegeneration (PKAN) Market Analysis

• The Pantothenate Kinase-Associated Neurodegeneration (PKAN) market is witnessing significant growth due to rising awareness of rare neurodegenerative disorders, increasing investment in research and development, and advancements in diagnostic and therapeutic solutions
• The escalating demand for PKAN diagnostics and therapies is primarily fueled by the growing prevalence of neurodegenerative disorders, increasing healthcare infrastructure, and a rising focus on early diagnosis and personalized treatment approaches
• North America dominated the pantothenate kinase associated neurodegeneration (PKAN) market with the largest revenue share of 39% in 2024, supported by a well-established healthcare infrastructure, favorable reimbursement policies, and active initiatives by key pharmaceutical and biotech players. The U.S. accounted for the majority of the regional revenue, driven by early adoption of innovative therapies, clinical trials, and widespread awareness programs
• Asia-Pacific is expected to be the fastest-growing region in the pantothenate kinase associated neurodegeneration (PKAN) market during the forecast period, driven by increasing healthcare investments, rising disposable incomes, and growing awareness of neurodegenerative conditions in countries such as China, India, and Japan
• The Classic segment dominated the pantothenate kinase associated neurodegeneration (PKAN) market with the largest market revenue share of 57.0% in 2024, driven by its early onset, severe disease progression, and well-characterized clinical symptoms. Classic PKAN patients are often diagnosed at younger ages, prompting immediate medical attention and long-term management strategies

Report Scope and Pantothenate Kinase associated Neurodegeneration (PKAN) Market Segmentation       

Pantothenate Kinase associated Neurodegeneration (PKAN) Market Trends

Rising Focus on Early Diagnosis and Treatment Accessibility

• A significant and accelerating trend in the global pantothenate kinase-associated neurodegeneration (PKAN) market is the increasing emphasis on early diagnosis and timely therapeutic intervention. Early detection of PKAN through genetic testing, MRI scans, and biomarker identification is becoming a priority for clinicians and healthcare providers, as it allows for better management of disease progression and improved patient outcomes

  • For instance, specialized PKAN clinics and research centers are expanding genetic screening programs for high-risk populations, ensuring that patients receive prompt and accurate diagnosis. Similarly, academic collaborations are developing standardized diagnostic protocols to identify both classic and atypical forms of the disorder at earlier stage

• The growing availability of targeted treatment options, including anti-convulsive drugs, dystonia management therapies, and supportive care, is driving demand for earlier intervention. Patients who are diagnosed sooner can benefit from comprehensive treatment plans, which may slow disease progression and enhance quality of life
• Increased awareness among healthcare professionals, combined with rising patient advocacy initiatives, is promoting broader adoption of diagnostic and treatment services in hospitals, private clinics, and research institutes worldwide. This expansion is helping address historical gaps in PKAN patient care
• The integration of clinical research findings into standard care practices further supports the development of more effective treatment regimens, ensuring that patients have access to both pharmacological and supportive therapies tailored to individual needs
• Growing investment in rare disease research and the establishment of specialized PKAN centers are strengthening infrastructure for diagnosis, treatment, and patient monitoring. These efforts are improving disease management and encouraging the adoption of comprehensive care approaches across geographies
• Overall, the focus on early diagnosis, improved treatment accessibility, and specialized care is fundamentally reshaping the PKAN market, driving adoption of advanced diagnostic tools and expanding the patient base served by hospitals, academic institutions, and private clinics

Pantothenate Kinase associated Neurodegeneration (PKAN) Market Dynamics

Driver

Growing Need Due to Rising Awareness and Advancements in PKAN Therapies

• The increasing prevalence of rare neurodegenerative disorders, coupled with growing awareness among healthcare providers and patients, is a significant driver for the heightened demand for PKAN diagnostics and therapies

  • For instance, in 2024, several key pharmaceutical and biotech companies announced advancements in targeted PKAN therapies and diagnostic tools, aiming to improve early detection and personalized treatment approaches. Such initiatives are expected to drive the PKAN market growth in the forecast period

• As healthcare systems and patients become more aware of the importance of early diagnosis, PKAN diagnostic solutions and therapies provide critical support in monitoring disease progression, enabling timely intervention, and improving patient outcomes
• Furthermore, the growing focus on rare neurological disorders and the development of specialized treatment protocols are making PKAN solutions an essential part of clinical research and therapeutic strategies
• The increasing availability of innovative PKAN therapies, expanding healthcare infrastructure, and improved access to treatment in emerging regions are key factors propelling the adoption of PKAN solutions in both developed and developing markets

Restraint/Challenge

Challenges Due to High Treatment Costs and Limited Awareness

• The high cost of advanced PKAN diagnostic tools and therapies poses a significant challenge to broader market adoption. Limited awareness among patients and healthcare providers about rare neurodegenerative disorders can further slow uptake

  • For instance, in some developing regions, limited access to specialized diagnostic centers and treatment options has hindered timely diagnosis and effective disease management

• Addressing these challenges through awareness campaigns, patient education, and the development of more cost-effective PKAN solutions is crucial for expanding market reach. Companies focusing on affordable diagnostics and therapy options are expected to improve accessibility and drive growth
• While gradual improvements in healthcare infrastructure and reimbursement policies are helping, the perceived premium cost for specialized PKAN therapies can still limit adoption, especially in price-sensitive regions
• Overcoming these challenges through enhanced patient education, government initiatives, and more widely available treatment options will be vital for sustained growth in the PKAN market

Pantothenate Kinase associated Neurodegeneration (PKAN) Market Scope

The market is segmented on the basis of form, diagnostic test, treatment, and end-user.

• By Form

On the basis of form, the pantothenate kinase associated neurodegeneration (PKAN) market is segmented into classic and atypical. The classic segment dominated the largest market revenue share of 57.0% in 2024, driven by its early onset, severe disease progression, and well-characterized clinical symptoms. Classic PKAN patients are often diagnosed at younger ages, prompting immediate medical attention and long-term management strategies. Healthcare providers prioritize comprehensive treatment plans combining pharmacological interventions and supportive therapies, which drives market adoption. Research programs and clinical trials focusing on classic PKAN further reinforce its market dominance. Patient awareness campaigns, early genetic screening programs, and the availability of disease-specific therapies also contribute to segment growth. Hospitals and specialty clinics often establish dedicated care protocols for Classic PKAN, strengthening its prevalence in the market.

The Atypical segment is expected to witness the fastest CAGR of 20.5% from 2025 to 2032, due to its later onset, milder progression, and variable clinical presentation. Growing awareness among neurologists about atypical presentations is driving early diagnosis and intervention. Advanced diagnostic tools, including genetic testing and MRI imaging, allow better differentiation of atypical cases, facilitating timely treatment. Patient-centric management, including symptom-targeted pharmacological therapy and rehabilitative support, encourages market uptake. Expansion of academic research and clinical programs focusing on atypical PKAN is increasing adoption. Technological integration of patient monitoring and follow-up further accelerates the segment’s growth trajectory. Atypical PKAN’s rising recognition in emerging markets also contributes to its rapid CAGR.

• By Diagnostic Test

On the basis of diagnostic test, the pantothenate kinase associated neurodegeneration (PKAN) market is segmented into Genetic Tests, MRI Scan, and Others. The Genetic Tests segment held the largest market revenue share of 48.3% in 2024, driven by the ability to detect PKAN at early stages and confirm specific mutations in the PANK2 gene. Genetic testing enables targeted treatment planning, improves prognosis prediction, and is increasingly integrated into neonatal and familial screening programs. Adoption is further supported by advances in next-generation sequencing and cost reductions in genetic analysis. Hospitals, academic centers, and specialized laboratories actively promote genetic testing for high-risk populations. Insurance coverage and reimbursement policies facilitate patient access. Continuous awareness campaigns highlighting the importance of early genetic diagnosis also bolster segment growth.

The MRI Scan segment is expected to witness the fastest CAGR of 22.0% from 2025 to 2032, driven by its non-invasive nature and ability to detect characteristic brain iron accumulation associated with PKAN. MRI imaging is critical for differential diagnosis and monitoring disease progression. Improvements in imaging resolution, software-based quantification of brain regions, and widespread availability of MRI facilities enhance adoption. Neurologists and radiologists increasingly rely on MRI to supplement genetic testing and guide treatment plans. The growing prevalence of PKAN and emphasis on early intervention in clinical guidelines further contribute to rapid segment growth. Academic research programs and clinical trials are also integrating advanced MRI diagnostics, supporting its high CAGR.

• By Treatment

On the basis of treatment, the pantothenate kinase associated neurodegeneration (PKAN) market is segmented into anti-convulsive drugs, drugs for dystonia, and other supportive treatment. The anti-convulsive drugs segment dominated the largest revenue share of 42.5% in 2024, as seizures are a common symptom in PKAN patients, especially those with classic forms. Clinicians prefer these drugs for managing neurological manifestations, ensuring patient safety, and improving quality of life. Availability in both branded and generic forms, combined with established dosing protocols, drives widespread adoption. Hospital pharmacies and specialty neurology clinics ensure continuous access. Ongoing clinical studies supporting efficacy reinforce market confidence. Patient adherence programs and caregiver support further enhance segment performance.

The Drugs for Dystonia segment is expected to witness the fastest CAGR of 21.8% from 2025 to 2032, due to increased focus on alleviating movement disorders and motor dysfunction in PKAN patients. Rising awareness among neurologists and physiatrists about symptom-specific therapies is boosting adoption. Clinical guidelines now recommend early pharmacological intervention to manage dystonia and prevent secondary complications. Pharmaceutical innovations, including novel formulations with reduced side effects, are attracting patients and clinicians. Integration with rehabilitative therapies and multidisciplinary care programs accelerates segment growth. Market expansion in emerging economies, supported by improved drug availability and healthcare infrastructure, also contributes to rapid adoption.

• By End-User

On the basis of end-user, the pantothenate kinase associated neurodegeneration (PKAN) market is segmented into hospitals, academic and research institutes, private clinics, and others. The Hospitals segment accounted for the largest market revenue share of 54.0% in 2024, driven by specialized neurological departments, multidisciplinary teams, and availability of advanced diagnostic and treatment facilities. Hospitals provide comprehensive patient care, including genetic testing, MRI scanning, pharmacological treatment, and rehabilitative support, which encourages patient preference. Institutional support, insurance coverage, and referral networks enhance market penetration. Hospitals also serve as centers for clinical trials and research, strengthening their dominance.

The Academic and Research Institutes segment is expected to witness the fastest CAGR of 19.7% from 2025 to 2032, fueled by the growing emphasis on rare disease research, early diagnosis programs, and development of innovative therapies. These institutes are increasingly collaborating with pharmaceutical companies and hospitals to facilitate clinical studies and genetic research. Expansion of laboratory infrastructure, availability of skilled personnel, and adoption of advanced diagnostic technologies drive rapid growth. Educational initiatives and patient registries managed by research centers also contribute to segment development. This segment’s rising influence in guideline development and novel therapy validation positions it as a key growth driver in the PKAN market.

Pantothenate Kinase associated Neurodegeneration (PKAN) Market Regional Analysis

• North America dominated the pantothenate kinase-associated neurodegeneration (PKAN) market with the largest revenue share of 39% in 2024, driven by a highly developed healthcare infrastructure, favorable reimbursement policies, and proactive initiatives by leading pharmaceutical and biotechnology companies
• The region benefits from strong government support for rare disease research, increasing patient and healthcare provider awareness, and widespread access to advanced diagnostic technologies
• In addition, collaborative clinical trials and research programs targeting PKAN therapies are expanding, further accelerating market adoption

U.S. Pantothenate Kinase-Associated Neurodegeneration (PKAN) Market Insight

The U.S. pantothenate kinase-associated neurodegeneration (PKAN) market captured the largest revenue share in 2024 within North America, fueled by early adoption of innovative therapies, extensive clinical trials, and comprehensive awareness programs for healthcare professionals and patients. The emphasis on early detection, personalized treatment approaches, and specialized care centers is supporting market growth. Furthermore, robust healthcare infrastructure and insurance coverage for rare neurological disorders reinforce the U.S.’s leading position in the PKAN market.

Europe Pantothenate Kinase-Associated Neurodegeneration (PKAN) Market Insight

The Europe pantothenate kinase-associated neurodegeneration (PKAN) market is projected to expand at a substantial CAGR throughout the forecast period, driven by continuous improvements in healthcare infrastructure, growing investment in rare disease research, and increasing patient awareness. Governments across the region are enhancing access to advanced diagnostics and therapies for neurodegenerative disorders. Rising urbanization, elevated healthcare expenditure, and expanding clinical research initiatives are further facilitating adoption of PKAN diagnostics and treatment solutions.

U.K. Pantothenate Kinase-Associated Neurodegeneration (PKAN) Market Insight

The U.K. pantothenate kinase-associated neurodegeneration (PKAN) market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by heightened awareness of rare neurodegenerative disorders, growing availability of specialized therapies, and supportive healthcare programs. The country’s robust healthcare system, emphasis on early detection, and adoption of innovative treatment protocols are expected to sustain market expansion, benefiting both patients and healthcare providers.

Germany Pantothenate Kinase-Associated Neurodegeneration (PKAN) Market Insight

The Germany pantothenate kinase-associated neurodegeneration (PKAN) market is expected to expand at a considerable CAGR during the forecast period, fueled by growing awareness among healthcare professionals, substantial investment in rare disease therapies, and well-established healthcare infrastructure. The adoption of advanced diagnostic methods, personalized treatment strategies, and ongoing research initiatives are driving significant market growth in both residential and clinical settings.

Asia-Pacific Pantothenate Kinase-Associated Neurodegeneration (PKAN) Market Insight

The Asia-Pacific pantothenate kinase-associated neurodegeneration (PKAN) market is poised to grow at the fastest CAGR during the forecast period, driven by increasing healthcare investments, rising disposable incomes, and heightened awareness of neurodegenerative disorders in countries such as China, India, and Japan. Government-led initiatives to improve access to diagnostics and treatments for rare diseases, coupled with expansion of healthcare infrastructure, are key factors fueling growth. In addition, increasing clinical research and the establishment of specialized care centers are supporting greater adoption of PKAN therapies in the region.

Japan Pantothenate Kinase-Associated Neurodegeneration (PKAN) Market Insight

The Japan pantothenate kinase-associated neurodegeneration (PKAN) market is gaining momentum due to the country’s advanced healthcare system, high-quality diagnostic facilities, and strong focus on rare disease management. Awareness campaigns targeting healthcare professionals and patients, combined with specialized treatment centers and active clinical research programs, are driving early diagnosis and the adoption of innovative therapies. The country’s emphasis on technological advancement and precision medicine further strengthens market growth.

China Pantothenate Kinase-Associated Neurodegeneration (PKAN) Market Insight

The China pantothenate kinase-associated neurodegeneration (PKAN) market accounted for the largest market revenue share in Asia-Pacific in 2024, supported by expanding healthcare infrastructure, growing disposable incomes, and increasing awareness of neurodegenerative disorders. Government initiatives to improve access to rare disease diagnostics and treatment, alongside significant investment in healthcare technology and research, are key growth drivers. In addition, the country’s large population and expanding middle class are creating a broader patient base, which is further strengthening PKAN market adoption.

Pantothenate Kinase associated Neurodegeneration (PKAN) Market Share

The pantothenate kinase associated neurodegeneration (PKAN) industry is primarily led by well-established companies, including:

• BridgeBio Pharma, Inc. (U.S.)
• CoA Therapeutics (U.S.)
• Virtus Therapeutics (U.S.)
• Travere Therapeutics, Inc. (U.S.)

Latest Developments in Global Pantothenate Kinase associated Neurodegeneration (PKAN) Market

• In March 2024, the National Brain Iron Accumulation Disorders Association (NBIA) announced significant advancements in PKAN gene therapy research. Collaborative efforts among researchers and newly formed partnerships have accelerated progress in developing gene therapy treatments for PKAN, offering hope for long-term solutions to this rare neurodegenerative disorder
• In August 2025, a study published in Scientific Reports utilized serum metabolomics to investigate ferroptosis in PKAN patients. The findings suggest that ferroptosis could be a primary cause of cell death in PKAN, providing new avenues for therapeutic intervention

SKU-63252